Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.
2018
KF1893.B56 .C37 2018 (Mapit)
Available at Stacks
Formats
| Format | |
|---|---|
| BibTeX | |
| MARCXML | |
| TextMARC | |
| MARC | |
| DublinCore | |
| EndNote | |
| NLM | |
| RefWorks | |
| RIS |
Items
Details
Author
Title
Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.
Edition
First edition.
Imprint
New York : Alfred A. Knopf, 2018.
Copyright
©2018
Description
x, 339 pages ; 25 cm
Formatted Contents Note
A purposeful life
The gluebot
Apple envy
Goodbye East Paly
The childhood neighbor
Sunny
Dr. J
The miniLab
The wellness play
"Who is LTC Shoemaker?"
Lighting a Fuisz
Ian Gibbons
Chiat\Day
Going live
Unicorn
The grandson
Fame
The Hippocratic Oath
The tip
The ambush
Trade secrets
La mattanza
Damage control
The empress has no clothes
Epilogue.
The gluebot
Apple envy
Goodbye East Paly
The childhood neighbor
Sunny
Dr. J
The miniLab
The wellness play
"Who is LTC Shoemaker?"
Lighting a Fuisz
Ian Gibbons
Chiat\Day
Going live
Unicorn
The grandson
Fame
The Hippocratic Oath
The tip
The ambush
Trade secrets
La mattanza
Damage control
The empress has no clothes
Epilogue.
Summary
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at 9 billion dollars, putting Holmes's worth at an estimated 4.7 billion dollars. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.
Note
"This is a Borzoi book."
Bibliography, etc. Note
Includes bibliographical references and index.
Location
STA
Course Lists
Selected Topics in Venture Capital by Fockler (SPRING 2023)
Call Number
KF1893.B56 .C37 2018
Language
English
ISBN
9781524731656 (hardcover)
152473165X (hardcover)
152473165X (hardcover)
Record Appears in